Hangzhou Tigermed Consulting Co.,Ltd. has announced its intention to participate in an investment fund.

The company plans to invest through its entity, Hangzhou Tigermed Equity Investment Partnership, in the Shanghai Sansheng Healthcare Private Equity Investment Fund Partnership.

The initial total committed capital for this fund is set at 950 million yuan.

Hangzhou Tigermed Consulting Co.,Ltd. (ASX: 300347)

Tigermed's investment vehicle will contribute 200 million yuan of its own capital as a limited partner in the fund.

The fund's investment strategy will concentrate on sectors including innovative drugs and advanced formulations, high-end medical devices, biotechnology, and sophisticated pharmaceutical equipment.

Establishing this industry-focused fund allows the company to leverage its specialized expertise in the biopharma and healthcare sector.

This move is aimed at broadening the company's investment avenues and generating investment returns.

The collaborative model is also expected to enhance the company's overall service capabilities and help develop a pipeline of high-quality projects.